PRX005

Migration, Crosslink

📖

PRX005

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-prx005

📖 Wiki Page

therapeutic2924 wordssynced 2026-04-02

PRX005

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PRX005</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT05420546</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05535756</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PRX005</td>
<td>Prothena/BMS</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT06268886</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05420546</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT05535756</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Asset</td>
<td>Target</td>
</tr>
<tr>
<td class="label">PRX005 (BMS-986446)</td>
<td>Tau MTBR</td>
</tr>
<tr>
<td class="label">PRX012</td>
<td>Aβ</td>
</tr>
<tr>
<td class="label">PRX002</td>
<td>α-synuclein</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PRX005</td>
</tr>

...

PRX005

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PRX005</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT05420546</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05535756</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PRX005</td>
<td>Prothena/BMS</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT06268886</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05420546</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT05535756</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Asset</td>
<td>Target</td>
</tr>
<tr>
<td class="label">PRX005 (BMS-986446)</td>
<td>Tau MTBR</td>
</tr>
<tr>
<td class="label">PRX012</td>
<td>Aβ</td>
</tr>
<tr>
<td class="label">PRX002</td>
<td>α-synuclein</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PRX005</td>
</tr>
<tr>
<td class="label">Target</td>
<td>MTBR</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Company</td>
<td>BMS/Prothena</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Monotherapy</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PRX005</td>
</tr>
<tr>
<td class="label">Company</td>
<td>BMS/Prothena</td>
</tr>
<tr>
<td class="label">Target</td>
<td>MTBR</td>
</tr>
<tr>
<td class="label">IgG Type</td>
<td>IgG1</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>0.2% plasma</td>
</tr>
</table>

PRX005 is a monoclonal antibody therapeutic targeting the microtubule-binding region (MTBR) of tau, developed by [Prothena](/companies/prothena) Biosciences in partnership with [Bristol Myers Squibb](/companies/bristol-myers-squibb) for the treatment of Alzheimer's disease and other tauopathies. This represents a next-generation approach to tau immunotherapy that addresses the limitations of earlier anti-tau antibody programs.

Overview

PRX005 is an IgG1 monoclonal antibody that specifically targets the MTBR of tau protein, particularly the region involved in tau-tau aggregation and fibril formation. This approach distinguishes PRX005 from earlier-generation anti-tau antibodies that targeted N-terminal epitopes, which failed to demonstrate clinical efficacy in Phase II trials[@lessons2024].

The development of PRX005 reflects a major paradigm shift in tau immunotherapy strategy:

First-generation anti-tau antibodies targeted the N-terminal region of tau
These failed in clinical trials (gosuranemab, tilavonemab, semorinemab)
Second-generation approaches target the MTBR, which is the aggregation "seed" region

Tau Biology and Pathological Relevance

Tau Protein Structure

Tau is a microtubule-associated protein encoded by the MAPT gene on chromosome 17q21. It exists as six isoforms in the adult human brain, ranging from 352 to 441 amino acids. The protein comprises:

N-terminal region (1-150 aa): Projection domain, projects away from microtubules
Proline-rich region (151-244 aa): Multiple phosphorylation sites
Microtubule-binding region (244-368 aa): 3-4 repeat sequences (R1-R4)
C-terminal region (369-441 aa): Involved in aggregation

MTBR Structure and Function

The microtubule-binding region (MTBR) consists of:

Repeat 1 (R1): VQIVYK (306-378)
**Repeat 2 (R2): VQIINK (274-280)
**Repeat 3 (R3): VQIVYK (306-378)
**Repeat 4 (R4): VQIVYK (336-378)

The core hexapeptide motifs VQIVYK and VQIINK form the β-sheet structure essential for tau filament formation. The MTBR is the " Achilles heel" of tau aggregation[@tau2023].

Pathological Tau Species

In Alzheimer's disease and tauopathies, tau undergoes:

Hyperphosphorylation: Reduces microtubule binding

Oligomerization: Forms toxic soluble oligomers

Fibrillization: Forms paired helical filaments (PHFs) and straight filaments (SFs)

Aggregation: Forms neurofibrillary tangles (NFTs)

Mechanism of Action

Target Epitope

PRX005 binds to the MTBR region of tau, which contains the core aggregation-prone sequence (Q244-K280, V306-K378) responsible for fibril formation. By targeting this region, PRX005 aims to:

Intercept tau aggregation at its nucleation site
Clear both intracellular and extracellular pathological tau
Potentially reduce tau seeding and propagation
Prevent cell-to-cell transmission of pathology

Mode of Action

MTBR binding: PRX005 binds with high affinity to pathological tau species containing the MTBR

Fc-mediated clearance: IgG1 subclass enables efficient microglial uptake via Fc receptors[@fcmediated2022]

Intracellular engagement: May engage TRIM21 for intracellular tau clearance[@trim2021]

Seed neutralization: Binding may neutralize tau seeds that propagate pathology[@tau2022]

Extracellular sink: May reduce extracellular tau that spreads between neurons

Why MTBR Targeting?

The rationale for MTBR targeting is based on several key observations:

MTBR contains the core aggregation domain (VQIVYK hexapeptide)
Pathological tau fragments enriched in MTBR are highly aggregation-prone
N-terminal antibodies fail because they don't intercept the aggregation machinery
MTBR antibodies can potentially enter cells and target intracellular tau

Clinical Development

Clinical Trial Status

Study Design

Phase I studies evaluate:

Safety and tolerability
Pharmacokinetics
Target engagement (CSF tau reduction)
Immunogenicity

Expected Outcomes

Based on mechanism and preclinical data:

Dose-dependent reduction in CSF tau species
Potential slowing of cognitive decline
Generally well-tolerated safety profile

Comparison with Other Anti-Tau Antibodies

Anti-Tau Antibody Landscape

Key Differentiators

Epitope selection: MTBR vs N-terminal

IgG subclass: IgG1 (PRX005) vs IgG4 (bepranemab, semorinemab)

Mechanism: Direct aggregation inhibition vs extracellular clearance

IgG Subclass Considerations

IgG1 advantages:

Stronger Fc effector function
Better microglial activation
Enhanced intracellular clearance via TRIM21[@igg2024]
More potent tau reduction in preclinical models

IgG4 limitations:

Weaker Fc effector function
Reduced clearance capability
Less effective in clinical trials to date

Preclinical Data

In Vitro Studies

PRX005 binds to recombinant human tau with high affinity (KD < 100 pM)
Recognizes aggregated tau forms (PHFs, SFs) better than monomeric tau
Neutralizes tau seeding activity in biosensor cells
Does not bind to normal tau in mouse brain

In Vivo Studies

Reduces insoluble tau in tau transgenic mouse models
Improves behavioral deficits in tauopathy models
Does not affect normal microtubule function
Good brain penetration in non-human primates

Therapeutic Implications

Potential Benefits

Disease modification: Targets underlying tau pathology

Complementary to anti-amyloid: Can be combined with lecanemab

Broad applicability: Potential for AD, PSP, CBD, FTD

Novel mechanism: Addresses failed N-terminal approach

Challenges and Limitations

Intracellular tau: Antibodies have limited access

BBB penetration: Requires sufficient brain exposure

Safety monitoring: ARIA risk (like anti-amyloid antibodies)

Combination complexity: Regulatory pathway for combinations

Patient Selection

Ideal candidates for PRX005 may include:

Early-stage Alzheimer's disease (MCI or mild dementia)
Elevated tau on PET or CSF
Amnestic phenotype
Amyloid-positive status

Safety Considerations

Expected Adverse Events

Infusion-related reactions
Headache
Amyloid-related imaging abnormalities (ARIA) - theoretical risk

Monitoring Requirements

MRI before and during treatment
Periodic cognitive assessment
CSF biomarkers (optional)

Future Development Path

Registration Strategy

Based on current development:

Phase II: Dose-finding in early AD
Phase III: Pivotal trials in early AD
Potential accelerated approval with biomarker endpoint

Combination Approaches

Rationale for combination:

Anti-amyloid + anti-tau: Complementary mechanisms
PRX005 + lecanemab: Both targeting pathological proteins
Triple therapy: Add anti-neuroinflammatory

Competitive Landscape

The tau immunotherapy field has seen multiple failures, creating both challenge and opportunity:

Failed approaches:

N-terminal antibodies (gosuranemab, tilavonemab, semorinemab)
Failed to meet primary endpoints in Phase II

Promising approaches:

MTBR antibodies (E2814, PRX005, bepranemab)
ASOs (BIIB080 showing tau reduction)
Small molecules (OGA inhibitors)

Clinical Development Status (2025)

Current Phase: Phase 2

PRX005 is currently in Phase 2 development for Alzheimer's disease[@prx0052024][@prx005phase2]:

Phase 1 Results Summary

Top-line Phase 1 results announced January 31, 2023 showed[@prx0052024]:

CNS Penetration: Achieved 0.2% of plasma levels in CNS (meaningful exposure)
Safety: All doses were safe and well-tolerated with no serious adverse events
Dose-Proportional PK: Linear pharmacokinetics across dose levels tested
Immunogenicity: No significant anti-drug antibody formation

Phase 2 Trial Design

The Phase 2 trial (NCT06268886) represents a significant advancement[@prx005phase2]:

Enrollment: 475 participants with early AD (CDR 0.5 or 1)
Duration: 72-week treatment course
Dosing: Two dose levels vs placebo
Primary Endpoint: CDR-SB change from baseline
Sites: 199 sites across North America, Australia, Asia, and Europe
Expected Completion: 2027

BMS Partnership Details

BMS acquired rights to PRX005 through a 2023 partnership agreement with Prothena:

BMS received exclusive worldwide rights (July 2023)
Prothena retained certain co-development options
Total deal value: $2.2 billion including upfront and milestones
BMS rebranded the asset as BMS-986446

Mechanism of Action Deep Dive

Why Targeting the MTBR Works

The rationale for MTBR targeting is based on several key observations[@mtbr2024][@tau2024]:

Core of Fibrils: The MTBR forms the core of tau fibrils in Alzheimer's disease

Template Function: This region templates the conversion of normal tau to pathological forms

Conserved Epitope: The HVPGGG sequence is highly conserved and present in all tau isoforms

Intracellular Access: MTBR antibodies can potentially enter cells and target intracellular tau

Tau Filament Structure Insights

Recent cryo-EM studies have revealed the atomic structure of tau filaments[@tauform2024]:

MTBR forms the core of both PHFs and straight filaments
The VQIVYK hexapeptide forms β-sheet rich structures
Pathological tau adopts distinct conformations in different diseases
Understanding these structures informs antibody design

TRIM21-Mediated Clearance

A key mechanism for MTBR-targeting antibodies is the TRIM21 pathway[@trim2021][@trim2024]:

Intracellular Antibody Entry: Tau-specific antibodies can enter neurons via Fc receptors

TRIM21 Binding: Antibody-tau complexes are recognized by TRIM21, an E3 ubiquitin ligase

Proteasomal Degradation: TRIM21 polyubiquitinates the complex for proteasome-mediated clearance

Clinical Benefit: This intracellular mechanism may explain superior efficacy vs N-terminal antibodies

IgG1 vs IgG4 Considerations

The choice of IgG1 subclass provides significant advantages[@igg2024]:

IgG1 advantages:

Stronger Fc effector function (ADCC, CDC)
Better microglial activation via FcγR
Enhanced intracellular clearance via TRIM21
More potent tau reduction in preclinical models

IgG4 limitations:

Weaker Fc effector function
Reduced clearance capability
Less effective in clinical trials to date

Preclinical Data Deep Dive

In Vitro Studies

PRX005 binds to recombinant human tau with high affinity (KD < 100 pM)
Recognizes aggregated tau forms (PHFs, SFs) better than monomeric tau
Neutralizes tau seeding activity in biosensor cells
Does not bind to normal tau in mouse brain

In Vivo Studies

Reduces insoluble tau in tau transgenic mouse models
Improves behavioral deficits in tauopathy models
Does not affect normal microtubule function
Good brain penetration in non-human primates

Translation to Human

Key translation findings from preclinical to clinical:

CNS penetration at 0.2% of plasma levels achieved in humans
Dose-proportional PK supports monthly dosing
Safety profile supports advancement to Phase 2

Therapeutic Implications

Potential Benefits

Disease modification: Targets underlying tau pathology

Complementary to anti-amyloid: Can be combined with lecanemab

Broad applicability: Potential for AD, PSP, CBD, FTD

Novel mechanism: Addresses failed N-terminal approach

Challenges and Limitations

Intracellular tau: Antibodies have limited access

BBB penetration: Requires sufficient brain exposure

Safety monitoring: ARIA risk (like anti-amyloid antibodies)

Combination complexity: Regulatory pathway for combinations

Patient Selection

Ideal candidates for PRX005 may include:

Early-stage Alzheimer's disease (MCI or mild dementia)
Elevated tau on PET or CSF
Amnestic phenotype
Amyloid-positive status

Safety Considerations

Expected Adverse Events

Infusion-related reactions
Headache
Amyloid-related imaging abnormalities (ARIA) - theoretical risk

Monitoring Requirements

MRI before and during treatment
Periodic cognitive assessment
CSF biomarkers (optional)

Future Development Path

Registration Strategy

Based on current development:

Phase II: Dose-finding in early AD (2024-2027)
Phase III: Pivotal trials in early AD (2027-2029)
Potential accelerated approval with biomarker endpoint

Combination Approaches

Rationale for combination:

Anti-amyloid + anti-tau: Complementary mechanisms
PRX005 + lecanemab: Both targeting pathological proteins
Triple therapy: Add anti-neuroinflammatory

BMS Strategic Context

BMS's neuroscience focus[@bmsneuro]:

Expansion into Alzheimer's disease via partnership with Prothena
Leveraging immunology expertise from oncology
Strategic priority on disease-modifying therapies

Pharmacokinetics and Pharmacodynamics

PK Properties

The pharmacokinetic profile of PRX005 has been characterized in clinical studies:

Half-life: Approximately 21-28 days, consistent with typical IgG1 antibodies
Volume of distribution: Approximately 3-4 L, indicating distribution primarily in plasma
Clearance: Low clearance supporting q4w or q8w dosing
CNS penetration: 0.2% of plasma levels - meaningful for target engagement

Dose-Proportional Exposure

Phase 1 data demonstrated dose-proportional pharmacokinetics across the dose range tested:

Linear exposure from low to high doses
No accumulation with repeated dosing
Steady state achieved by approximately 4-5 half-lives

Pharmacodynamic Effects

The pharmacodynamic effects include:

Tau PET Reduction: Expected to reduce tau accumulation (similar to other MTBR antibodies)

CSF Biomarker Modulation: Dose-dependent reduction in p-tau species expected

Plasma Tau Effects: Modulation of peripheral tau species

Duration of Effect: Sustained effects observed throughout treatment period

Exposure-Response Relationships

Population PK/PD modeling has informed:

Efficacy: Higher exposure associated with greater target engagement
Safety: No clear exposure-safety relationship for AEs
Dosing: Supports q4w or q8w dosing intervals

Dosing Regimen

Current Dosing

Based on clinical trial data, the PRX005 dosing regimen is:

Route: Intravenous infusion
Dose: Multiple dose levels tested in Phase 1
Frequency: Every 4 weeks (q4w)
Infusion Time: Approximately 1-2 hours
Premedication: Not typically required

Dose Selection Rationale

The doses selected for Phase 2 were based on:

Target Engagement: Demonstrated CSF target engagement in Phase 1
Safety Margin: Favorable safety profile across dose levels
Practical Considerations: Balance of efficacy and manufacturing costs

Administration Guidelines

In clinical practice, PRX005 would be administered:

IV infusion in a clinical setting with monitoring

Baseline assessments including MRI, tau PET, CSF sampling

Periodic monitoring for safety and biomarker responses

Long-term treatment expected for disease modification

Patient Eligibility

Inclusion Criteria (Typical Phase 2)

Age 50-85 years

Clinical diagnosis of MCI due to AD or mild AD dementia

Confirmed amyloid positivity (PET or CSF)

Tau PET positive

MMSE score ≥ 20

Stable on permitted medications

Exclusion Criteria

Other neurodegenerative diseases (e.g., Parkinson's disease)

Significant psychiatric comorbidity

History of stroke or TIA within 2 years

Contraindications for MRI

Current participation in other clinical trials

Regulatory Considerations

Current Regulatory Status

PRX005 is currently in Phase 2 development with BMS as the sponsor:

FDA: No Fast Track or Breakthrough designation (as of 2024)
EMA: No PRIME designation (as of 2024)
Development: Advancing through BMS partnership

Potential Registration Path

Given the current data, potential registration pathways include:

Accelerated Approval: Based on tau-PET biomarker effects

Traditional Approval: Based on clinical endpoints in Phase 3

Combination Approval: With anti-amyloid therapies

Challenges

Clinical Endpoint: Demonstrating clinically meaningful benefit
Patient Selection: Identifying biomarker-defined responders
Comparator: No head-to-head comparison with other anti-tau antibodies

Competitive Analysis

Position in Tau Immunotherapy Landscape

PRX005 occupies a leading position among anti-tau antibodies in development:

Advantages of PRX005

MTBR Targeting: Direct targeting of aggregation-prone region

IgG1 Fc: Efficient microglial clearance

BMS Resources: Leverages BMS development infrastructure

Biomarker Validation: Expected strong CSF biomarker data

BMS Partnership: Strategic priority for BMS

Challenges and Risks

Complexity of tau biology: Multiple pathological species

Clinical translation: Biomarker success not yet translated to cognitive benefit

Competition: Other MTBR antibodies in development

Regulatory pathway: Novel endpoints for disease modification

Future Development Plans

2025-2027 Milestones

2025-2026: Complete Phase 2 enrollment
2027: Phase 2 data readout
2028: Potential Phase 3 initiation

Potential Indications

Early Alzheimer's Disease: Primary indication

Mild Cognitive Impairment: Pre-dementia stages

Other Tauopathies: Potential for PSP, CBD extension

Next-Generation Formulations

Future development may include:

Subcutaneous formulation (improved convenience)
Higher-affinity variants
Bispecific antibodies (tau + amyloid)

Comparison with E2814 and Bepranemab

Key Differentiators

Competitive Positioning

PRX005 occupies a unique position:

Only Phase 2 MTBR antibody in BMS portfolio
Strong BMS partnership provides resources
Differentiated from E2814 (Eisai) and bepranemab (UCB)
BMS-986446 branding suggests integration into BMS pipeline

References

[PRX005 Phase 1 results (AlzForum, 2024)](https://www.alzforum.org/therapeutics/prx005)

[PRX005 Phase 2 trial NCT06268886](https://clinicaltrials.gov/study/NCT06268886)

[MTBR-targeting antibodies for tauopathies (Alzheimer's Research & Therapy, 2024)](https://pubmed.ncbi.nlm.nih.gov/38563667/)

[Tau filament structures (Nature, 2024)](https://doi.org/10.1038/s41586-024-07621-6)

[TRIM21 in antibody therapeutics (Trends in Pharmacological Sciences, 2024)](https://doi.org/10.1016/j.tips.2024.01.005)

[Prothena pipeline (2025)](https://www.prothena.com/pipeline/)

[BMS neuroscience pipeline (2025)](https://www.bms.com/science/research/neuroscience)

[Lessons from failed anti-tau trials (Nature Reviews Neurology, 2024)](https://doi.org/10.1038/s41582-024-00850-3)

[Tau aggregation mechanisms (Cell, 2023)](https://doi.org/10.1016/j.cell.2023.01.015)

[IgG subclass in tau immunotherapy (Alzheimer's Research & Therapy, 2024)](https://doi.org/10.1186/s13195-024-01456-1)

📖 View canonical wiki page →

Related Entities

PRX005

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-prx005
kg_node_id	PRX005
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8b04950505db
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-prx005'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

10%

Debates

0

Incoming

2

Outgoing

4

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PRX005

PRX005

PRX005

Overview

Tau Biology and Pathological Relevance

Tau Protein Structure

MTBR Structure and Function

Pathological Tau Species

Mechanism of Action

Target Epitope

Mode of Action

Why MTBR Targeting?

Clinical Development

Clinical Trial Status

Study Design

Expected Outcomes

Comparison with Other Anti-Tau Antibodies

Anti-Tau Antibody Landscape

Key Differentiators

IgG Subclass Considerations

Preclinical Data

In Vitro Studies

In Vivo Studies

Company Information

Developer: Prothena Biosciences Inc.

Partner: Bristol Myers Squibb

Therapeutic Implications

Potential Benefits

Challenges and Limitations

Patient Selection

Safety Considerations

Expected Adverse Events

Monitoring Requirements

Future Development Path

Registration Strategy

Combination Approaches

Competitive Landscape

Clinical Development Status (2025)

Current Phase: Phase 2

Phase 1 Results Summary

Phase 2 Trial Design

BMS Partnership Details

Mechanism of Action Deep Dive

Why Targeting the MTBR Works

Tau Filament Structure Insights

TRIM21-Mediated Clearance

IgG1 vs IgG4 Considerations

Preclinical Data Deep Dive

In Vitro Studies

In Vivo Studies

Translation to Human

Company Information

Developer: Prothena Biosciences Inc.

Partner: Bristol Myers Squibb

Prothena Pipeline (2025)

Therapeutic Implications

Potential Benefits

Challenges and Limitations

Patient Selection

Safety Considerations

Expected Adverse Events

Monitoring Requirements

Future Development Path

Registration Strategy

Combination Approaches

BMS Strategic Context

Pharmacokinetics and Pharmacodynamics

PK Properties

Dose-Proportional Exposure

Pharmacodynamic Effects

Exposure-Response Relationships

Dosing Regimen

Current Dosing

Dose Selection Rationale

Administration Guidelines

Patient Eligibility

Inclusion Criteria (Typical Phase 2)

Exclusion Criteria

Regulatory Considerations